A resurging boom in new drugs for epilepsy and brain disorders

  title={A resurging boom in new drugs for epilepsy and brain disorders},
  author={Iyan Younus and Doodipala Samba Reddy},
  journal={Expert Review of Clinical Pharmacology},
  pages={27 - 45}
  • Iyan Younus, D. Reddy
  • Published 2 January 2018
  • Medicine, Psychology, Biology
  • Expert Review of Clinical Pharmacology
ABSTRACT Introduction: Epilepsy is one of the most common neurological diseases affecting approximately 50 million people worldwide. Despite many advances in epilepsy research, nearly a third of patients with epilepsy have refractory or pharmacoresistant epilepsy. Despite the approval of a dozen antiepileptic drugs (AEDs) over the past decade, there are no agents that halt the development of epilepsy. Thus, newer and better AEDs that can prevent refractory seizures and modify the disease are… 
Investigational small molecules in phase II clinical trials for the treatment of epilepsy
Three small molecule drugs in phase II clinical trials: Cannabidivarin, BGG492 (Selurampanel) and Ganaloxone are reviewed and further clinical innovations will define the future for these small molecule-type drugs in epilepsy therapeutics.
Antiepileptic Drugs in Pediatrics.
The history and evolution of AED development, features of specific AEDs with a focus on the newest generation, and examples of Aeds in development are reviewed.
Timing use of novel anti-epileptic drugs: is earlier better?
Third-generation AEDs may offer better tolerability, milder adverse effects, less drug interactions and improved pharmacokinetic characteristics compared to the conventional AEDS, and may be used earlier and earlier in epileptic patients.
Cenobamate for the treatment of focal epilepsies
This article reviews animal studies, pharmacokinetics, pharmacodynamics, and the phase 1 to 3 trials and open-label extension data on cenobamate, the latest approved antiepileptic drug in focal epilepsy.
Genetic variations associated with pharmacoresistant epilepsy
A comprehensive understanding of the role of genetic variation in drug resistance will help develop improved strategies to regulate drug resistance efficiently and determine the pathophysiological processes that underlie this common human neurological disease.
Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy
Ganaxolone is a synthetic analog of the endogenous neurosteroid allopregnanolone and a member of a novel class of neuroactive steroids called epalons and may lead to indications for use in clinical practice.
Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy
  • S. Chuang, D. Reddy
  • Biology, Psychology
    The Journal of Pharmacology and Experimental Therapeutics
  • 2018
Recent advances in molecular regulation of extrasynaptic GABA-A receptor–mediated tonic inhibition are providing unique new therapeutic approaches for epilepsy, status epilepticus, and certain brain disorders.
Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women
  • D. Reddy
  • Medicine, Biology
    Journal of neuroendocrinology
  • 2021
The benefits of neurosteroid replacement therapy for the management of neuroendocrine disorders such as catamenial epilepsy, postpartum depression, PPD and premenstrual brain conditions are emphasized.
Searching for New Leads To Treat Epilepsy: Target-Based Virtual Screening for the Discovery of Anticonvulsant Agents
A virtual screening protocol that involved the search into molecular databases of new compounds and known drugs to find small molecules that interact with the open conformation of the Nav1.2 pore confirmed the anticonvulsant action of Valsartan, Ciprofloxacin, and N, N'-diphenethylsulfamide.


Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy.
  • B. Clossen, D. Reddy
  • Psychology, Medicine
    Biochimica et biophysica acta. Molecular basis of disease
  • 2017
Progress in Epilepsy: Latest Waves of Discovery.
Recent advances and future prospects that are aligning to help realize epilepsy goals are described, including advancing the understanding of epilepsy and its comorbid conditions, the prevention of epilepsy, improving treatment options while limiting adverse effects, and mitigating the adverse consequences of seizures.
The role of inflammation in epilepsy
This work focuses on the rapidly growing body of evidence that supports the involvement of inflammatory mediators—released by brain cells and peripheral immune cells—in both the origin of individual seizures and the epileptogenic process.
Optogenetic tools for modulating and probing the epileptic network
The Biochemistry and Epigenetics of Epilepsy: Focus on Adenosine and Glycine
  • D. Boison
  • Psychology, Biology
    Front. Mol. Neurosci.
  • 2016
New findings based on biochemical manipulation of the DNA methylome suggest that: (i) epigenetic mechanisms play a functional role in epileptogenesis; and (ii) therapeutic reconstruction of the epigenome is an effective antiepileptogenic therapy.
The Pharmacological Basis of Cannabis Therapy for Epilepsy
The pharmacological basis of cannabis therapy is highlights, with an emphasis on the endocannabinoid mechanisms underlying the emerging neurotherapeutics of CBD in epilepsy, and a rigorous clinical evaluation of pharmaceutical CBD products is needed to establish the safety and efficacy of their use in the treatment of epilepsy.
Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment
The rationale for the discovery and preclinical profile of brivaracetam (BRV), currently under regulatory review as adjunctive therapy for adults with partial‐onset seizures, is described and it is revealed BRV had a greater antiepileptogenic potential than LEV.
Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish
It is hypothesized that the anti-epileptiform activity of FA not only originates from its 5- HT1D- and 5-HT2C-agonism, but likely also from its ability to block σ1 receptors, which could contribute to the therapeutic effect of the compound.
New avenues for anti-epileptic drug discovery and development
It is proposed that future anti-epileptic drug development may be improved through a new joint endeavour between academia and the industry, through the identification and application of tools for new target-driven approaches, and through comparative preclinical proof-of-concept studies and innovative clinical trials designs.